VJHemOnc is committed to improving our service to you

IMW 2019 | AML: hybridoma vaccines

VJHemOnc is committed to improving our service to you

David Avigan

David Avigan, MD, Harvard Medical School, Boston, MA, discusses the use of dendritic cell/tumour cell hybridoma vaccines for the treatment of acute myeloid leukemia (AML). Dr Avigan goes on to discuss the impressive efficacy data achieved with the use of this therapy and how hypomethylating agents may hold the key to increasing its potency further. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter